
Pelacarsen 63 items
Trials, agents, guidance
- Trial Lp(a)FRONTIERS APHERESIS
- Agent Pelacarsen (TQJ230, AKCEA-APO(a)-LRx)
- Trial Lp(a)HORIZON
- Trial Pelacarsen phase 2 (AKCEA-APO(a)-LRx)
Studies
- Lp(a)HORIZON: pelacarsen lowers Lp(a) by 78 percent but does not reduce cardiovascular events, hazard ratio 1.02 (Cho et al., NEJM 2026)
- Pelacarsen (AKCEA-APO(a)-LRx) lowers Lp(a) by up to 80 percent in patients with cardiovascular disease: the phase 2 trial (Tsimikas et al., NEJM 2020)
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)
- Design and rationale of Lp(a)HORIZON, the first Lp(a) outcomes trial: pelacarsen in 8,323 patients (Cho, Nicholls, Nordestgaard et al., Am Heart J 2025)
- IONIS-APO(a)Rx and the GalNAc-conjugated APO(a)-LRx: two dose-ranging trials (Viney et al., Lancet 2016)
- First antisense drug against apo(a) in humans: ISIS-APO(a)Rx phase 1 (Tsimikas et al., Lancet 2015)
- Potent Lp(a) lowering with apo(a) antisense reduces pro-inflammatory activation of monocytes (Stiekema et al., EHJ 2020)
- Pelacarsen lowers Lp(a) cholesterol and reveals how much of 'LDL-C' is really Lp(a) (Yeang et al., JACC 2022)
- Lp(a) and its significance in cardiovascular disease: a review (Duarte Lau and Giugliano, JAMA Cardiol 2022)
- Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) (NEJM Evid 2026)
- Olpasiran tops a network meta-analysis of 51 trials (17,810 patients) ranking Lp(a)-lowering therapies against PCSK9 inhibitors (Diabetes Obes Metab 2026)
- Olpasiran leads a network meta-analysis of 25 trials (7,715 patients) ranking every Lp(a)-lowering agent (Pharmacol Res 2026)
- Olpasiran ranks as the most effective Lp(a)-lowering therapy, network meta-analysis of 1,432 patients (Front Cardiovasc Med 2026)
- Pelacarsen cut Lp(a) by 80% in phase 2, letting 98% of patients reach target levels, as the 7,680-patient Lp(a)HORIZON outcomes trial enrolls, a JACC Focus Seminar (J Am Coll Cardiol 2021)
- Pelacarsen lowers Lp(a) by 86% in Black and Hispanic participants with ASCVD (Lp(a)FRONTIERS EXPANSION) (Circ Popul Health Outcomes 2026)
- Five late-stage RNA and small-molecule Lp(a) therapies near approval, from pelacarsen to muvalaplin (Curr Atheroscler Rep 2026)
- Twenty clinical trials map the Lp(a)-lowering therapeutic landscape across three drug classes, review (J Clin Med 2026)
- From apheresis to CRISPR: review maps every Lp(a)-lowering therapy in development (Curr Atheroscler Rep 2026)
- Lp(a)FRONTIERS EXPANSION enrols 422 Black and Hispanic patients for a pelacarsen trial, ahead of schedule (Am J Prev Cardiol 2026)
- Olpasiran and pelacarsen cut Lp(a) by 85-90%, with phase 3 outcome trials testing whether this prevents aortic stenosis progression (Int J Mol Sci 2023)
- Gene-silencing drugs cut Lp(a) by 70-90% and LDL-C by over 30%, positioning PCSK9 and Lp(a) as the leading targets for RNA-based cardiovascular therapy, a review (Clin Ther 2023)
- About 20% of people carry elevated Lp(a), and phase 3 outcome trials of pelacarsen and olpasiran are now testing whether lowering it reduces cardiovascular events (Annu Rev Pharmacol Toxicol 2024)
- Every RNA-based Lp(a) drug tested lowers it by more than 90%, a systematic assessment of 22 trials of pelacarsen, olpasiran, SLN360 and LY3819469 (J Cardiovasc Pharmacol 2023)
- Pelacarsen does not alter platelet reactivity via thromboxane A2 or P2Y12 pathways in 275 patients on aspirin or dual antiplatelet therapy (J Thromb Thrombolysis 2023)
- Trial design challenges for Lp(a)-lowering therapies take center stage as pelacarsen and olpasiran enter phase 3 outcomes trials, a JACC Focus Seminar (J Am Coll Cardiol 2023)
- Pelacarsen lowers Lp(a) by up to 106% in healthy Japanese subjects, supporting the 80 mg monthly dose used in the Lp(a)HORIZON trial (J Clin Lipidol 2023)
- Pelacarsen and olpasiran achieve up to 90% Lp(a) reductions, positioning routine Lp(a) testing as clinically essential, a review (Curr Opin Lipidol 2023)
- Pelacarsen lowers Lp(a) equally regardless of LPA genotype or apo(a) isoform size, a pooled analysis of 455 patients across 4 trials (Atherosclerosis 2021)
- Individualised, phenotype-guided dyslipidaemia management for stroke prevention, review covering Lp(a)-lowering agents (Int J Stroke 2026)
- Structural model separates functional LPA gene variants from bystanders shaping Lp(a) and CAD risk, review (Prog Lipid Res 2026)
- Lp(a) biology and the full emerging-therapy pipeline, review spanning ASOs to CRISPR and obicetrapib (Cardiovasc Drugs Ther 2026)
- Olpasiran and pelacarsen could be cost-effective at AU$1867 and AU$984 per year for secondary prevention of coronary heart disease, an early Australian health technology assessment (J Clin Lipidol 2024)
- New ASO and siRNA drugs cut Lp(a) by up to 98%, far beyond what existing lipid-lowering therapies achieve, a review argues we are not yet ready to treat Lp(a) (Curr Atheroscler Rep 2023)
- Traditional Lp(a) drugs barely reach 50% reduction while new RNA-interfering agents may exceed 95%, a review of emerging pharmacotherapies (Int J Mol Sci 2023)
- Pelacarsen, olpasiran and SLN360 lower Lp(a) by up to 90%, with pelacarsen phase 3 outcome trial due in 2024, a review (Curr Atheroscler Rep 2022)
- Lp(a)-lowering could become the third pillar of lipid therapy alongside LDL-C and triglycerides, a Dutch perspective on eradicating lipid-driven cardiovascular risk (Neth Heart J 2022)
- Pelacarsen cuts Lp(a) by up to 80%, one of five RNA-targeted drugs reshaping dyslipidaemia treatment, a review (Curr Atheroscler Rep 2021)
- APO(a)Lrx (pelacarsen) can cut Lp(a) by up to 80%, far surpassing PCSK9 inhibitors, in patients where Lp(a) explains 5-20% of suspected FH diagnoses, a review (J Clin Med 2020)
- Guidelines recommend once-in-a-lifetime Lp(a) measurement in nmol/L for all adults (Clin Chem 2026)
- Pelacarsen and Lp(a)HORIZON: interpreting the disconnect between lipoprotein(a) lowering and cardiovascular outcomes (Am J Med 2026)
- Lp(a) confers residual risk after myocardial infarction and requires repeat measurement after clinical stabilization (Biomedicines 2026)
- RNA-directed therapies lower Lp(a) by up to 97% in phase 2 trials, while phase 3 pelacarsen missed its primary endpoint (Curr Atheroscler Rep 2026)
- Pelacarsen phase 3 Lp(a)HORIZON trial shows no primary endpoint benefit despite 80-95% Lp(a) reduction in phase 2 (J Cardiovasc Pharmacol 2026)
- Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease
- Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives
- Lp(a) rises as kidney function declines, adding unaddressed cardiovascular risk in CKD, review (Cardiorenal Med 2026)
- Lp(a)-targeted RNA therapies cut levels by 80-100%, but outcome data are still pending, Korean review (Korean Circ J 2026)
- About 20% of Europeans have elevated Lp(a) that current lipid drugs cannot adequately lower, but four RNA-based agents in trials could close that gap, a review (Pharmaceuticals 2022)
- Pelacarsen, olpasiran and SLN360 headline a wave of recent Lp(a)-lowering RNA trials, with outcomes data the next frontier, a review (Curr Opin Lipidol 2022)
- PCSK9 inhibitors modestly lower Lp(a) with cardiovascular benefit independent of LDL-C, while apheresis remains the most effective option, a review of modern approaches (Biomedicines 2021)
- No FDA-approved drug specifically lowers Lp(a) yet, but pelacarsen could change that, a clinical pharmacology review (Am J Cardiovasc Drugs 2022)
- Whether Lp(a)-raising gene variants add predictive value beyond Lp(a) concentration itself remains controversial, a review of a decade of advances (Pharmacol Res 2021)
- APO(a)LRx leads the field of antisense oligonucleotides targeting Lp(a)-driven residual cardiovascular risk, a review (J Cardiovasc Pharmacol 2021)
Video and podcasts

